{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:59:31Z","timestamp":1774533571265,"version":"3.50.1"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1196900"],"award-info":[{"award-number":["1196900"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1196560"],"award-info":[{"award-number":["1196560"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.drugalcdep.2025.112699","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T17:05:55Z","timestamp":1746723955000},"page":"112699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploring psychedelic experiences among people who regularly use methamphetamine: Findings from an international survey"],"prefix":"10.1016","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9265-9798","authenticated-orcid":false,"given":"Dilara","family":"Bahceci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6534-3325","authenticated-orcid":false,"given":"Krista","family":"Siefried","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Steele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Harrod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgina","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1015-9379","authenticated-orcid":false,"given":"Monica J.","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Nicholas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter S.","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0888-095X","authenticated-orcid":false,"given":"Christopher S.","family":"Stauffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5690-2263","authenticated-orcid":false,"given":"Paul","family":"Liknaitzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3065-7495","authenticated-orcid":false,"given":"Jonathan","family":"Brett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2025.112699_bib1","first-page":"1","article-title":"What predicts beneficial outcomes in psychedelic use? A quantitative content analysis of psychedelic health outcomes","author":"Acevedo","year":"2024","journal-title":"J. Psychoact. Drugs"},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112699_bib2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1021\/acsptsci.1c00018","article-title":"Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes","volume":"4","author":"Agin-Liebes","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112699_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11011-014-9496-5","article-title":"Psychiatric disorders in individuals with methamphetamine dependence: prevalence and risk factors","volume":"29","author":"Akindipe","year":"2014","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib4","unstructured":"Australian Criminal Intelligence Commission, 2022. National Wastewater Drug Monitoring Program Report 16."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib5","unstructured":"Australian Institute of Health and Welfare, 2024. Methamphetamine and Amphetamine in the NDSHS. Canberra (AU)."},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112699_bib6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/02698811231224217","article-title":"Interactions between classic psychedelics and serotonergic antidepressants: effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study","volume":"38","author":"Barbut Siva","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib7","article-title":"Moving on from representativeness: testing the utility of the global drug survey","volume":"11","author":"Barratt","year":"2017","journal-title":"Subst. Abus. Res. Treat."},{"issue":"12","key":"10.1016\/j.drugalcdep.2025.112699_bib8","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0269881116678781","article-title":"The Challenging Experience Questionnaire: characterization of challenging experiences with psilocybin mushrooms","volume":"30","author":"Barrett","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.paid.2017.06.004","article-title":"Neuroticism is associated with challenging experiences with psilocybin mushrooms","volume":"117","author":"Barrett","year":"2017","journal-title":"Personal. Individ. Differ."},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112699_bib10","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cpt.2487","article-title":"Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects","volume":"111","author":"Becker","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.drugalcdep.2025.112699_bib11","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1111\/add.16200","article-title":"Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis","volume":"118","author":"Bharat","year":"2023","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.112699_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.drugalcdep.2025.112699_bib13","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.112699_bib14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0893-133X(95)00145-4","article-title":"Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans","volume":"14","author":"Bonson","year":"1996","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112699_bib15","doi-asserted-by":"crossref","first-page":"15998","DOI":"10.1038\/s41598-023-41145-x","article-title":"Case analysis of long-term negative psychological responses to psychedelics","volume":"13","author":"Bremler","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib16","doi-asserted-by":"crossref","first-page":"1123424","DOI":"10.3389\/fpsyt.2023.1123424","article-title":"Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder","volume":"14","author":"Brett","year":"2023","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2025.112699_bib17","doi-asserted-by":"crossref","first-page":"1490907","DOI":"10.3389\/fpsyt.2024.1490907","article-title":"Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use","volume":"15","author":"Brett","year":"2024","journal-title":"Front. Psychiatry"},{"issue":"12","key":"10.1016\/j.drugalcdep.2025.112699_bib18","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0269881116662634","article-title":"Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences","volume":"30","author":"Carbonaro","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.112699_bib19","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.drugalcdep.2025.112699_bib20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.addbeh.2014.01.018","article-title":"Correlates of nonmedical use of stimulants and methamphetamine use in a national sample","volume":"39","author":"Chen","year":"2014","journal-title":"Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.schres.2024.03.037","article-title":"Positive and negative symptoms in methamphetamine-induced psychosis compared to schizophrenia: a systematic review and meta-analysis","volume":"267","author":"Cohen-Laroque","year":"2024","journal-title":"Schizophr. Res."},{"issue":"12","key":"10.1016\/j.drugalcdep.2025.112699_bib22","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1111\/add.13897","article-title":"Rates, characteristics and circumstances of methamphetamine-related death in Australia: a national 7-year study","volume":"112","author":"Darke","year":"2017","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112699_bib23","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/sltb.12442","article-title":"Completed suicide among methamphetamine users: a national study","volume":"49","author":"Darke","year":"2019","journal-title":"Suicide Life Threat. Behav."},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112699_bib24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/0269881120967878","article-title":"Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD","volume":"35","author":"Davis","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib25","series-title":"Use of Brief Screening Instrument for Psychosis: Results of a ROC Analysis","author":"Degenhardt","year":"2005"},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112699_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5694\/mja15.00671","article-title":"Estimating the number of regular and dependent methamphetamine users in Australia, 2002-2014","volume":"204","author":"Degenhardt","year":"2016","journal-title":"Med. J. Aust."},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112699_bib27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/dar.12426","article-title":"Crystalline methamphetamine use and methamphetamine-related harms in Australia","volume":"36","author":"Degenhardt","year":"2017","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib28","doi-asserted-by":"crossref","first-page":"1134454","DOI":"10.3389\/fpsyt.2023.1134454","article-title":"Therapeutic effect of psilocybin in addiction: a systematic review","volume":"14","author":"van der Meer","year":"2023","journal-title":"Front. Psychiatry"},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.112699_bib29","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/16066359.2017.1388373","article-title":"The pitfalls of prevalence estimation: the case of regular and dependent methamphetamine use in Australia","volume":"26","author":"Dietze","year":"2018","journal-title":"Addict. Res. Theory"},{"issue":"10","key":"10.1016\/j.drugalcdep.2025.112699_bib30","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","article-title":"Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder","volume":"47","author":"D'Souza","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"10209","key":"10.1016\/j.drugalcdep.2025.112699_bib31","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/S0140-6736(19)32230-5","article-title":"Responding to global stimulant use: challenges and opportunities","volume":"394","author":"Farrell","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.drugalcdep.2025.112699_bib32","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881119845793","article-title":"Cessation and reduction in alcohol consumption and misuse after psychedelic use","volume":"33","author":"Garcia-Romeu","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib33","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3389\/fpsyt.2019.00955","article-title":"Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey","volume":"10","author":"Garcia-Romeu","year":"2019","journal-title":"Front. Psychiatry"},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.112699_bib34","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaclp.2020.12.012","article-title":"A \u201ctrip\u201d to the intensive care unit: an intravenous injection of psilocybin","volume":"62","author":"Giancola","year":"2021","journal-title":"J. Acad. Consult. Liaison Psychiatry"},{"issue":"12","key":"10.1016\/j.drugalcdep.2025.112699_bib35","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40263-014-0209-8","article-title":"Methamphetamine psychosis: epidemiology and management","volume":"28","author":"Glasner-Edwards","year":"2014","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112699_bib36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/10550490701756070","article-title":"Risk factors for suicide attempts in methamphetamine-dependent patients","volume":"17","author":"Glasner-Edwards","year":"2008","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib37","doi-asserted-by":"crossref","first-page":"1349565","DOI":"10.3389\/fpsyt.2024.1349565","article-title":"Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey","volume":"15","author":"Glynos","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2025.112699_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/7854_2021_298","article-title":"Effects of setting on psychedelic experiences, therapies, and outcomes: a rapid scoping review of the literature","volume":"56","author":"Golden","year":"2022","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"12","key":"10.1016\/j.drugalcdep.2025.112699_bib39","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.112699_bib40","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.drugalcdep.2025.112699_bib41","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/02698811231179910","article-title":"Attenuation of psilocybin mushroom effects during and after SSRI\/SNRI antidepressant use","volume":"37","author":"Gukasyan","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib42","first-page":"9","article-title":"Predicting responses to psychedelics: a prospective study","author":"Haijen","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.drugalcdep.2025.112699_bib43","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/jamapsychiatry.2021.2588","article-title":"Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.112699_bib44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/02791072.2017.1290855","article-title":"Examination of the phenomenology of the ibogaine treatment experience: role of altered states of consciousness and psychedelic experiences","volume":"49","author":"Heink","year":"2017","journal-title":"J. Psychoact. Drugs"},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.112699_bib45","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","article-title":"Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects","volume":"47","author":"Holze","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drugalcdep.2025.112699_bib46","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jad.2024.01.197","article-title":"Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United Kingdom","volume":"351","author":"Honk","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"10","key":"10.1016\/j.drugalcdep.2025.112699_bib47","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1177\/02698811241269669","article-title":"Altered states of consciousness in Danish healthy volunteers and recreational users of psilocybin and the possible impact of setting and intention: Danish validation of the five-dimensional altered states of consciousness questionnaire","volume":"38","author":"Hovmand","year":"2024","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112699_bib48","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1176\/ajp.126.4.481","article-title":"LSD in the treatment of alcoholism","volume":"126","author":"Johnson","year":"1969","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112699_bib49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am. J. Drug Alcohol Abus."},{"issue":"11","key":"10.1016\/j.drugalcdep.2025.112699_bib50","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112699_bib51","first-page":"35","article-title":"Who is the typical psychedelics user? Methodological challenges for research in psychedelics use and its consequences","volume":"38","author":"Johnstad","year":"2021","journal-title":"Nord. Alkohol Nark."},{"issue":"12","key":"10.1016\/j.drugalcdep.2025.112699_bib52","doi-asserted-by":"crossref","first-page":"317","DOI":"10.15585\/mmwr.mm6912a1","article-title":"Patterns and characteristics of methamphetamine use among adults - United States, 2015-2018","volume":"69","author":"Jones","year":"2020","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib53","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jad.2024.10.058","article-title":"Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. Participants of Color: a longitudinal online survey study","volume":"370","author":"Jones","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112699_bib54","doi-asserted-by":"crossref","first-page":"16976","DOI":"10.1038\/s41598-022-18645-3","article-title":"Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality","volume":"12","author":"Jones","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112699_bib55","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1038\/s41598-022-06580-2","article-title":"Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study","volume":"12","author":"Jones","year":"2022","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.drugalcdep.2025.112699_bib56","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1111\/add.16259","article-title":"Hallucinogen use among young adults ages 19-30 in the United States: changes from 2018 to 2021","volume":"118","author":"Keyes","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2025.112699_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108715","article-title":"LSD use in the United States: trends, correlates, and a typology of us","volume":"223","author":"Killion","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.917199","article-title":"Psychedelics, mystical experience, and therapeutic efficacy: a systematic review","volume":"13","author":"Ko","year":"2022","journal-title":"Front. Psychiatry"},{"issue":"12","key":"10.1016\/j.drugalcdep.2025.112699_bib59","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.5665\/sleep.5232","article-title":"The association between sleep problems and psychotic symptoms in the general population: a global perspective","volume":"38","author":"Koyanagi","year":"2015","journal-title":"Sleep"},{"issue":"9","key":"10.1016\/j.drugalcdep.2025.112699_bib60","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1002\/hbm.23234","article-title":"LSD-induced entropic brain activity predicts subsequent personality change","volume":"37","author":"Lebedev","year":"2016","journal-title":"Hum. Brain Mapp."},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.112699_bib61","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1111\/dar.13670","article-title":"Methamphetamine exposure and depression-a systematic review and meta-analysis","volume":"42","author":"Leung","year":"2023","journal-title":"Drug Alcohol Rev."},{"issue":"11","key":"10.1016\/j.drugalcdep.2025.112699_bib62","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/s41386-023-01607-2","article-title":"Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants","volume":"48","author":"Ley","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.112699_bib63","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/02791072.2023.2228303","article-title":"Psychedelic experiences after bereavement improve symptoms of grief: the influence of emotional breakthroughs and challenging experiences","volume":"56","author":"Low","year":"2023","journal-title":"J. Psychoact. Drugs"},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112699_bib64","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/02698811231196877","article-title":"Psychological and physiological effects of extended DMT","volume":"38","author":"Luan","year":"2024","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112699_bib65","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/02791072.2020.1769878","article-title":"A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy","volume":"52","author":"Luoma","year":"2020","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.drugalcdep.2025.112699_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.647909","article-title":"Sustained, multifaceted improvements in mental well-being following psychedelic experiences in a prospective opportunity sample","volume":"12","author":"Mans","year":"2021","journal-title":"Front. Psychiatry"},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.112699_bib67","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/02698811241232548","article-title":"Psychiatric risks for worsened mental health after psychedelic use","volume":"38","author":"Marrocu","year":"2024","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112699_bib68","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/02791072.2022.2129885","article-title":"Predictors of psychedelic experience: a thematic analysis","volume":"55","author":"McCartney","year":"2023","journal-title":"J. Psychoact. Drugs"},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112699_bib69","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/0193841X0102500202","article-title":"A review of temporal effects and outcome predictors in substance abuse treatment studies with long-term follow-ups. Preliminary results and methodological issues","volume":"25","author":"McKay","year":"2001","journal-title":"Eval. Rev."},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112699_bib70","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/09595230601146652","article-title":"Socio-demographic factors associated with methamphetamine treatment contact among dependent methamphetamine users in Sydney, Australia","volume":"26","author":"McKetin","year":"2007","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib71","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eclinm.2019.09.014","article-title":"Mental health outcomes associated with of the use of amphetamines: a systematic review and meta-analysis","volume":"16","author":"McKetin","year":"2019","journal-title":"eClinicalMedicine"},{"issue":"5","key":"10.1016\/j.drugalcdep.2025.112699_bib72","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s10597-020-00563-1","article-title":"Methamphetamine abuse trends in psychiatric emergency services: a retrospective analysis using big data","volume":"56","author":"Miller","year":"2020","journal-title":"Community Ment. Health J."},{"issue":"5","key":"10.1016\/j.drugalcdep.2025.112699_bib73","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/a-1524-2794","article-title":"Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports","volume":"54","author":"Nayak","year":"2021","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112699_bib74","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1089\/psymed.2022.0008","article-title":"Proposed consensus statement on defining psychedelic drugs","volume":"1","author":"Nichols","year":"2022","journal-title":"Psychedelic Med."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109127","article-title":"Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations","volume":"214","author":"Ortiz","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drugalcdep.2025.112699_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108089","article-title":"Trends in characteristics of individuals who use methamphetamine in the United States, 2015-2018","volume":"213","author":"Palamar","year":"2020","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112699_bib77","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12954-022-00662-0","article-title":"Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience","volume":"19","author":"Palmer","year":"2022","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.884703","article-title":"Changes in mental health, wellbeing and personality following ayahuasca consumption: results of a naturalistic longitudinal study","volume":"13","author":"Perkins","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib79","doi-asserted-by":"crossref","first-page":"1066369","DOI":"10.3389\/fpsyt.2022.1066369","article-title":"The association between naturalistic use of psychedelics and co-occurring substance use disorders","volume":"13","author":"Rabinowitz","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2025.112699_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103149","article-title":"Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial","volume":"82","author":"Rieser","year":"2025","journal-title":"eClinicalMedicine"},{"issue":"9","key":"10.1016\/j.drugalcdep.2025.112699_bib81","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/0269881119855974","article-title":"Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory","volume":"33","author":"Roseman","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib83","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-022-06083-y","article-title":"Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review","author":"Sarparast","year":"2022","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.112699_bib84","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s11469-014-9510-5","article-title":"Treatment motivation predicts substance use treatment retention across individuals with and without co-occurring mental illness","volume":"12","author":"Shields","year":"2014","journal-title":"Int. J. Ment. Health Addict."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib85","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.neubiorev.2021.09.016","article-title":"Methamphetamine abuse disturbs the dopaminergic system to impair hippocampal-based learning and memory: an overview of animal and human investigations","volume":"131","author":"Shukla","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112699_bib86","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40263-020-00711-x","article-title":"Pharmacological treatment of methamphetamine\/amphetamine dependence: a systematic review","volume":"34","author":"Siefried","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drugalcdep.2025.112699_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115349","article-title":"Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: a systematic review and individual participant data meta-analysis","volume":"327","author":"Simonsson","year":"2023","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib88","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jad.2023.01.073","article-title":"Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics","volume":"326","author":"Simonsson","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib89","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2024.0047","article-title":"Adolescent psychedelic use and psychotic or manic symptoms","author":"Simonsson","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112699_bib90","doi-asserted-by":"crossref","first-page":"10195","DOI":"10.1038\/s41598-024-60890-1","article-title":"Personality traits explain the relationship between psychedelic use and less depression in a comparative study","volume":"14","author":"Sj\u00f6str\u00f6m","year":"2024","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112699_bib91","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40519-020-01000-8","article-title":"Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder","volume":"26","author":"Spriggs","year":"2021","journal-title":"Eat. Weight Disord."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112699_bib92","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/02791072.2022.2039815","article-title":"Contextual parameters associated with positive and negative mental health in recreational psychedelic users","volume":"55","author":"St Arnaud","year":"2023","journal-title":"J. Psychoact. Drugs"},{"issue":"10","key":"10.1016\/j.drugalcdep.2025.112699_bib93","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1111\/add.14706","article-title":"Mortality among people with regular or problematic use of amphetamines: a systematic review and meta-analysis","volume":"114","author":"Stockings","year":"2019","journal-title":"Addiction"},{"issue":"13","key":"10.1016\/j.drugalcdep.2025.112699_bib94","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41386-023-01609-0","article-title":"Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants","volume":"48","author":"Straumann","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drugalcdep.2025.112699_bib95","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jsat.2019.09.005","article-title":"Psychological treatment for methamphetamine use and associated psychiatric symptom outcomes: a systematic review","volume":"109","author":"Stuart","year":"2020","journal-title":"J. Subst. Abus. Treat."},{"issue":"8","key":"10.1016\/j.drugalcdep.2025.112699_bib96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012412","article-title":"Psychometric evaluation of the altered states of consciousness rating scale (OAV)","volume":"5","author":"Studerus","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.drugalcdep.2025.112699_bib97","unstructured":"Substance Abuse and Mental Health Services Administration, 2022. The 2021 National Survey on Drug Use and Health (NSDUH) Annual National Report."},{"issue":"5","key":"10.1016\/j.drugalcdep.2025.112699_bib98","doi-asserted-by":"crossref","first-page":"799","DOI":"10.15288\/jsad.2018.79.799","article-title":"Polysubstance use by stimulant users: health outcomes over three years","volume":"79","author":"Timko","year":"2018","journal-title":"J. Stud. Alcohol Drugs"},{"issue":"13","key":"10.1016\/j.drugalcdep.2025.112699_bib99","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2218949120","article-title":"Human brain effects of DMT assessed via EEG-fMRI","volume":"120","author":"Timmermann","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112699_bib100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/1874473708666150107120930","article-title":"A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment","volume":"7","author":"Turton","year":"2014","journal-title":"Curr. Drug Abus. Rev."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib101","unstructured":"United Nations Office on Drugs and Crime, 2021. World Drug Report 2021: Booklet 4 - Drug Market Trends: Cocaine, Amphetamine-type Stimulants. Vienna (AT)."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112699_bib102","first-page":"172","article-title":"Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants","volume":"13","author":"Vogt","year":"2023","journal-title":"Curr. Drug Abus. Rev."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib103","first-page":"491","article-title":"A comparison of methamphetamine-induced psychosis and schizophrenia: a review of positive, negative, and cognitive symptomatology","volume":"9","author":"Wearne","year":"2018","journal-title":"Curr. Drug Abus. Rev."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib104","article-title":"LSD use in the United States: examining user demographics and their evolution from 2015\u20132019","author":"Weleff","year":"2024","journal-title":"J. Psychedelic Stud."},{"issue":"9","key":"10.1016\/j.drugalcdep.2025.112699_bib105","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1046\/j.1360-0443.2002.00185.x","article-title":"The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility","volume":"97","author":"WHO ASSIST Working Group","year":"2002","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112699_bib106","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1017\/S0033291721002531","article-title":"LSD, madness and healing: mystical experiences as possible link between psychosis model and therapy model","volume":"53","author":"Wie\u00dfner","year":"2023","journal-title":"Psychol. Med."},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112699_bib107","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/15563650.2024.2346612","article-title":"The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics","volume":"62","author":"Wilkes","year":"2024","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115524","article-title":"Social-geographic disparities in suicidal ideations among methamphetamine users in the USA","volume":"329","author":"Xing","year":"2023","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib109","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jad.2020.07.037","article-title":"The ultra brief checklist for suicidality","volume":"276","author":"Yoon","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.drugalcdep.2025.112699_bib110","doi-asserted-by":"crossref","first-page":"1183740","DOI":"10.3389\/fpsyt.2023.1183740","article-title":"Psychedelic therapy in the treatment of addiction: the past, present and future","volume":"14","author":"Zafar","year":"2023","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2025.112699_bib111","article-title":"Associations between psychedelic use and cannabis use disorder in a nationally representative sample","volume":"266","author":"Zech","year":"2024","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112699_bib112","doi-asserted-by":"crossref","first-page":"13645","DOI":"10.1038\/s41598-023-40856-5","article-title":"Co-use of MDMA with psilocybin\/LSD may buffer against challenging experiences and enhance positive experiences","volume":"13","author":"Zeifman","year":"2023","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112699_bib113","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13362","article-title":"Analysing the behaviour change of brain regions of methamphetamine abusers using electroencephalogram signals: hope to design a decision support system","volume":"29","author":"Zolfaghari","year":"2024","journal-title":"Addict. Biol."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625001528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625001528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:03:41Z","timestamp":1774530221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871625001528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":113,"alternative-id":["S0376871625001528"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112699","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring psychedelic experiences among people who regularly use methamphetamine: Findings from an international survey","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112699","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112699"}}